Navigation Links
InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
Date:10/28/2013

BOSTON, Oct. 28, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will host a conference call to discuss its MASTER trial 12-month follow up data on October 30, 2013 at 8:30 a.m. ET / 5:30 a.m. PT.

Joining the call will be Alan Milinazzo, President and Chief Executive Officer, Craig Chore, Chief Financial Officer, and Dr. Campbell Rogers, a member of InspireMD's Board of Directors.

Participants should call (877) 842-0788 (United States/Canada) or (317) 468-2947 (International) and request the InspireMD call or provide confirmation code 90920442. A live webcast of the call will be available on the Investor Relations section of the Company's website at http://www.inspire-md.com/site_en/for-investors/. Please allow 10 minutes prior to the call to visit the site and download any necessary audio software.

A replay of the conference call will be available approximately two hours after completion of the live conference call and will be accessible until 11:59 p.m. ET on November 13, 2013. To listen to the replay, dial (855) 859-2056 (United States/Canada) or (404) 537-3406 (International) and enter code 90920442. The webcast of the event will also be archived for a limited time on the Investor Relations section of the Company's website at http://www.inspire-md.com/site_en/for-investors/.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
2. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
3. InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
4. InspireMD Announces Participation in Two Investor Conferences in September
5. InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services
6. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
7. InspireMD Reports Financial Results For Period Ended March 31, 2013
8. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
9. InspireMD Closes $25 Million Underwritten Public Offering
10. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Leading Countries, Technologies and Companies ... at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% ... of 9.1% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business ...
(Date:2/27/2017)... Israel , Feb. 27, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced ... M.D., Ph.D., FACP, and Arturo O. Araya , ... "Dr. Almenoff and Mr. Araya are talented and ... time for our company," said Chaim Lebovits , ...
(Date:2/27/2017)... , Feb 27, 2017 The ... by NATO for use at the security level RESTRICTED. The ... the NATO organization for the communication of classified information. ... Sectra and ... with an eavesdrop-secure smartphone solution. Sectra Tiger/R is developed by ...
Breaking Medicine Technology:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 INAB ... (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets ...
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today ... 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical ... behavioral health analytics to improve Medicaid population health management. , ODH will also have ...
(Date:2/24/2017)... ... 2017 , ... Houston dentist , Dr. Behzad Nazari, ... Center. Currently, patients can get single dental implants for $3,599 and All On ... more about these offers by contacting Antoine Dental Center. Both of these options ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only ... jobs in the United States may be taken over by technology in the next ... who steamrolls over colleagues is drawing to a close. Success will belong to those ...
Breaking Medicine News(10 mins):